Menu

Latest News

Here you can find all the latest news from the MRC CTU at UCL.

New results from the STAMPEDE trial metformin comparison were presented at the 2024 ESMO Congress.
New results from the PATCH and STAMPEDE trials could increase the treatment options available for people with prostate cancer who are starting long-term hormone therapy.
As part of our 25th anniversary celebrations, we look at the many achievements of the STAMPEDE clinical trial, which has tested 10 different treatments and changed the standard-of-care for prostate cancer four times in less than 20 years.
Final results from the RADICALS-HD clinical trial found no evidence that the addition of hormone therapy improved how long people lived without their cancer spreading, among patients whose doctors considered them suitable for short-term, long-term or no hormone therapy.
We will present our latest prostate cancer research from the PATCH, STAMPEDE and STAMPEDE2 trials at the 2024 ESMO Congress.